Statistical Programmer
Regeneron Pharmaceuticals
Summary
The Statistical Programmer provides support to the lead programmer and the study team on all programming activities according to the study requirements and the timelines. This role contributes to studies in various therapeutic areas and all clinical trial phases.
Job description
Discover your role
- Provide programming support within multiple studies/projects in various study activities with timely and high-quality programming deliverables in assigned tasks and projects
- Work with lead programmer and manager in cross-functional collaborations to support the study conduct and reporting activities
- Maintain all documentation in accordance with SOPs/Guidance/WI/process to ensure traceability and regulatory compliance
- Participate and contribute towards department goals and SME topics
- Adhere to Regeneron processes and policies around retention of data, records, and information for clinical trials
- Show commitment to and perform consistently to ensure high quality deliverables
Requirements
- Bachelor's degree with 2+ years or Master's degree with 1+ years of programming experience preferably in processing clinical trial data in the biotechnology, pharmaceutical or health related industry
- Proficiency in SAS
- Knowledge of other programming languages such as R, Python is a plus
- Good knowledge of pharmaceutical clinical development (statistical concepts, techniques, clinical trial principles) is a plus
- Ability to work on global interdisciplinary teams
- Good organizational, interpersonal, and communication skills
- Positive attitude, team player and growth mindset
Benefits
- Annual bonuses
- Incentive plans
- Equity awards
- Pension or retirement benefits
- 401(k) company match
- Health and wellness programs
- Fitness centers
- Medical, Dental & Vision
- Life and disability insurance
- Paid time off
- Family support benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.